PL1807431T3 - Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38 - Google Patents

Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38

Info

Publication number
PL1807431T3
PL1807431T3 PL05814296T PL05814296T PL1807431T3 PL 1807431 T3 PL1807431 T3 PL 1807431T3 PL 05814296 T PL05814296 T PL 05814296T PL 05814296 T PL05814296 T PL 05814296T PL 1807431 T3 PL1807431 T3 PL 1807431T3
Authority
PL
Poland
Prior art keywords
kinases
jnk
jun
pyrrolo
triazine
Prior art date
Application number
PL05814296T
Other languages
English (en)
Inventor
Qing Dong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1807431T3 publication Critical patent/PL1807431T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05814296T 2004-10-26 2005-10-25 Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38 PL1807431T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62251904P 2004-10-26 2004-10-26
EP05814296A EP1807431B1 (en) 2004-10-26 2005-10-25 Pyrrolo[1,2-d][1,2-4]triazine as inhibitors of c-jun n-terminal kinases (jnk) and p-38 kinases
PCT/US2005/038071 WO2006047354A1 (en) 2004-10-26 2005-10-25 Pyrrolo [1,2-d][1,2-4]triazine as inhibitors of c-jun n terminal kinases (jnk) and p-38 kinases

Publications (1)

Publication Number Publication Date
PL1807431T3 true PL1807431T3 (pl) 2011-03-31

Family

ID=35825463

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05814296T PL1807431T3 (pl) 2004-10-26 2005-10-25 Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38

Country Status (16)

Country Link
US (1) US7855288B2 (pl)
EP (1) EP1807431B1 (pl)
JP (1) JP2008517933A (pl)
KR (1) KR20070064350A (pl)
CN (1) CN101035791B (pl)
AT (1) ATE480542T1 (pl)
AU (1) AU2005299730B2 (pl)
BR (1) BRPI0518277A2 (pl)
CA (1) CA2580475A1 (pl)
DE (1) DE602005023504D1 (pl)
ES (1) ES2350771T3 (pl)
MX (1) MX2007004935A (pl)
PL (1) PL1807431T3 (pl)
PT (1) PT1807431E (pl)
RU (1) RU2007119448A (pl)
WO (1) WO2006047354A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026802A2 (en) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk inhibitors for treatment of skin diseases
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
US8349832B2 (en) 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
CN103221389B (zh) * 2010-11-29 2016-01-20 日产化学工业株式会社 异硫氰酸酯化合物的制造方法
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014143606A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750522A (en) 1995-07-13 1998-05-12 American Home Products Corporation Pyrrolo 1,2-d! 1,2,4!triazine derivatives
NZ525334A (en) * 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
EP1497019B1 (en) * 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
MX2007004935A (es) 2007-06-12
ES2350771T3 (es) 2011-01-26
EP1807431B1 (en) 2010-09-08
CN101035791A (zh) 2007-09-12
KR20070064350A (ko) 2007-06-20
AU2005299730A1 (en) 2006-05-04
CN101035791B (zh) 2010-12-08
JP2008517933A (ja) 2008-05-29
PT1807431E (pt) 2010-11-18
AU2005299730B2 (en) 2009-11-12
EP1807431A1 (en) 2007-07-18
BRPI0518277A2 (pt) 2008-11-11
CA2580475A1 (en) 2006-05-04
US20080253988A1 (en) 2008-10-16
RU2007119448A (ru) 2008-12-10
DE602005023504D1 (de) 2010-10-21
ATE480542T1 (de) 2010-09-15
US7855288B2 (en) 2010-12-21
WO2006047354A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
PL1807431T3 (pl) Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38
SG196855A1 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
SG166100A1 (en) Novel compounds
TW200618800A (en) Heterocyclic compounds
SG166771A1 (en) Novel compounds
TW200833687A (en) Substituted piperidines
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
EP1604665A4 (en) C-KIT KINASE HEMMER
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
SI1644376T1 (sl) Derivati pirolo c pirazola ki so aktivni kotzaviralci kinaze
WO2004009597A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2006061417A3 (en) Macrocyclic quinazole derivatives and their use as mtki
WO2006047503A3 (en) Inhibitors of c-fms kinase
TW200513461A (en) Organische verbindungen
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
WO2007147103A3 (en) Novel compounds
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
IL164606A0 (en) Novel compounds
WO2005097755A3 (de) Imidazolderivate als hemmer von tyrosinkinase
TW200503722A (en) Substituted 7-aza-quinazoline compounds
AU2003268464A8 (en) Indole-type derivatives as inhibitors of p38 kinase
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
UA88794C2 (en) Pyrrolopyrazoles, potent kinase inhibitors